10-Q: Ava Bio Shifts to Biotech, Reports Reduced Loss Amidst Capital Needs

Avant Technologies, soon to be Ava Bio, reported a reduced net loss for Q2 2026, signaling a strategic pivot towards biotech through new joint ventures while facing ongoing capital requirements and internal control deficiencies.

Summary

• The company changed its name from Avant Technologies Inc. to Ava Bio, Inc., effective September 5, 2025, reflecting a strategic shift towards biotechnology.
• Reported a net loss of $940,605 for the six months ended September 30, 2025, an 18% decrease from $1,151,889 in the prior year period.
• Total operating expenses decreased by 23% to $882,255 for the six months ended September 30, 2025, primarily due to lower consulting services and amortization expense.
• Cash and cash equivalents increased to $91,995 as of September 30, 2025, from $81,053 as of March 31, 2025.
• Entered into a Joint Venture and License Agreement with Austrianova to form Klothonova Inc. on September 15, 2025, focusing on cell encapsulation technology, with AVAI contributing up to $1.5 million.
• Subsequent to the reporting period, formed another joint venture, Insulinova, Inc., with Austrianova on November 1, 2025, also focused on cell encapsulation technology, with AVAI contributing up to $1.5 million.
• Terminated the Equity Financing Agreement with GHS Investments LLC on May 13, 2025, and withdrew the related S-1 registration statement, aiming for a revised equity financing structure with a higher minimum floor price of $2 per share.
• Management concluded that disclosure controls and procedures were not effective as of September 30, 2025, due to lack of resources and reliance on outside consultants.
• The company has a substantial doubt about its ability to continue as a going concern, dependent on additional investment capital.

Sentiment

Score: 2

Explanation: The company faces severe financial challenges, including no revenue, a substantial accumulated deficit, and a going concern warning. While the net loss decreased and there's a strategic pivot into biotech with new joint ventures, these are early-stage initiatives requiring significant capital that is not yet secured. The ineffectiveness of internal controls further adds to the negative sentiment.

Positives

• Net loss decreased by 18% to $940,605 for the six months ended September 30, 2025, compared to $1,151,889 in the prior year.
• Total operating expenses decreased by 23% to $882,255 for the six months ended September 30, 2025, driven by lower consulting services and amortization.
• Cash and cash equivalents increased to $91,995 as of September 30, 2025, from $81,053 as of March 31, 2025.
• Strategic pivot into the biotech sector through new joint ventures (Klothonova and Insulinova) with Austrianova, a company with significant expertise in cell encapsulation technology.
• Termination of the GHS Investments ELOC and S-1 registration statement to pursue a revised equity financing structure with a higher minimum floor price of $2 per share, potentially reducing dilution for future investors.

Negatives

• No revenue generated for the three and six months ended September 30, 2025, and 2024.
• Accumulated deficit increased to $5,059,115 as of September 30, 2025, from $4,118,510 as of March 31, 2025.
• Working capital deficit increased to $2,419,336 as of September 30, 2025, from $1,695,484 as of March 31, 2025.
• Total liabilities significantly increased to $2,532,131 as of September 30, 2025, from $1,788,617 as of March 31, 2025.
• Other expenses increased by 405% to $58,350 for the six months ended September 30, 2025, primarily due to discounts on convertible notes.
• Substantial doubt about the company's ability to continue as a going concern.
• Disclosure controls and procedures were not effective as of September 30, 2025, due to lack of resources and reliance on outside consultants.
• High dependence on additional investment capital to fund operating expenses and implement business plans.

Risks

• Limited operating history in an evolving industry makes it difficult to evaluate future prospects and increases the risk of not being successful.
• Difficulty in forecasting revenues and planning operating expenses, expanding the business, assimilating acquisitions, adapting to evolving technology trends, avoiding service interruptions, developing scalable infrastructure, hiring and retaining personnel, and managing rapid growth.
• Inability to generate revenue from acquired technologies (Avant! AI, InstantFAME) despite significant investment.
• Results of operations have not resulted in profitability, and there is no assurance of achieving profitability going forward.
• Incurred a net loss of $940,605 for the six months ended September 30, 2025, and expects net losses to continue, increasing working capital deficiency.
• Operations have not generated positive cash flow since inception, and the ability to generate positive cash flow is uncertain.
• Requires additional capital to support business growth and continue operations, with an estimated need of $10,000,000 to fully implement the business plan.
• Future issuances of equity or convertible debt securities could result in significant dilution for existing stockholders.
• Debt financing could involve restrictive covenants.
• Inability to obtain adequate financing on favorable terms could impair business growth and operations.
• Dependence on key personnel and the need for additional personnel; loss of qualified personnel could materially and adversely affect business operations.
• Business requires substantial capital, and inability to maintain adequate cash flows could jeopardize operations.
• Limited public market for common stock (OTC QB), leading to potential significant volatility and difficulty selling shares.
• Failure to maintain an effective system of internal controls, potentially leading to inaccurate financial reporting or fraud.
• Termination of the Wired4Health APA indicates a failed acquisition.
• Cybersecurity oversight gaps due to lack of a formal enterprise risk management program or a board cybersecurity subcommittee.
• Dependence on equity/debt issuance, which may be dilutive, carry high interest, or impose restrictive covenants.
• Stock price and trading volume may be volatile.
• No plans to pay cash dividends in the foreseeable future.
• Shares eligible for future sale (Rule 144) may adversely affect the market.
• Future equity offerings may cause dilution and new securities could have superior rights.
• Charter documents and Nevada law may inhibit a takeover.
• Limitations on director/officer liability.
• Penny stock regulations may impose restrictions on marketability of securities.
• FINRA sales practice requirements may limit a stockholder's ability to buy and sell stock.

Future Outlook

The company intends to position itself to raise additional funds through capital markets to fund operating expenses, with an estimated need of $10 million to fully implement its business plan. It is pursuing a revised equity financing structure with a higher minimum floor price of $2 per share after terminating a previous agreement. The company is strategically shifting towards biotechnology through new joint ventures (Klothonova and Insulinova) and continues to develop AI technologies. Management anticipates continued dependence on external investment for the near future.

Management Comments

• "We believe that our technology can provide a self-sustained system that prepares its data from unlabeled information (Unsupervised Clustering), and then analyzes it using various, proprietary, supervised learning techniques, thereby improving data efficiency."
• "Avants mission is to provide innovative and effective AI solutions that transform businesses and positively impact society. Avant strives to push the boundaries of AI technology and empower organizations to achieve their full potential."
• "In the opinion of management, the financial statements contain all material adjustments, consisting only of normal adjustments considered necessary to present fairly the financial condition, results of operations, and cash flows of the Company for the interim periods presented."
• "Management anticipates that the Company will be dependent, for the near future, on additional investment capital to fund operating expenses."
• "The Company intends to position itself so that it will be able to raise additional funds through the capital markets."
• "Our management is developing plans to alleviate the negative trends and conditions described above."
• "We intend to increase managements review of our financials."

Industry Context

The company is undergoing a significant strategic pivot, moving from its initial focus on AI and IT consulting (Avant! AI, InstantFAME, Ainnova Tech) towards the biotechnology sector with the formation of Klothonova and Insulinova joint ventures. This shift aligns with broader trends of technological convergence, where AI applications are increasingly integrated into healthcare and biotech for areas like disease detection and novel therapeutic delivery systems (e.g., cell encapsulation). The company's initial AI focus on unsupervised and supervised learning for data efficiency and factual discovery positions it to potentially leverage these capabilities in its new biotech ventures, particularly in data-intensive fields like retinal disease detection and cell-based product development. However, this pivot also introduces new market and regulatory challenges inherent to the highly regulated and capital-intensive biotech industry.

Comparison to Industry Standards

• The company's lack of revenue generation and recurring losses are significantly below industry standards for established technology or biotech companies.
• The substantial doubt about the ability to continue as a going concern is a critical indicator of financial distress, far from industry benchmarks for financial stability.
• The reported ineffectiveness of disclosure controls and procedures due to lack of resources and reliance on outside consultants falls short of best practices for corporate governance and financial reporting in publicly traded companies, regardless of size.
• The company's reliance on debt and equity financing for operations, coupled with a significant working capital deficit, contrasts sharply with profitable, cash-generating industry peers.
• The strategic shift into biotech with JVs like Klothonova and Insulinova, while potentially innovative, lacks specific comparable project results or market penetration data to assess against established biotech players like Novartis, Roche, or smaller, specialized cell therapy companies. The stated capital contributions ($1.5M for each JV) are relatively small compared to the R&D budgets of major biotech firms.
• The previous acquisition and subsequent cancellation of Wired4Health assets suggest potential issues with due diligence or integration, which is not a standard positive outcome in M&A.

Management Changes

Corporate Governance

Legal Proceedings

• Not currently a party to any legal proceedings, and not aware of any pending or potential legal actions.

Related Party Transactions

• Loan from Secretary Natalija Tunevic: $114,328 (unsecured, non-interest bearing, due on demand).
• Loan from Director Vitalis Racius: $128,263 (unsecured, non-interest bearing, due on demand).
• Loan from Shareholder Marieta Seiranova: $7,000 (unsecured, non-interest bearing, due on demand).
• Loan from Shareholder Mehrabian Investments LLC: $30,000 (unsecured, non-interest bearing, due on demand).
• Loan from Shareholder IGOR 1 CORP: $296,202 (unsecured, non-interest bearing, due on demand).
• Advances to subsidiary Thynews Tech LLC from related parties: $124,590 (interest-free, due on demand).
• Conversion of accounts payable into common shares for related parties.
• Conversion of salary debt into restricted common shares for Mrs. Tunevic ($114,600 for 9,550,000 shares).
• Issuance of common stock to Vitalis Racius for related party loan ($54,000).
• Issuance of preferred stock as bonuses to officers (Vitalis Racius, Ivan Lunegov, Natalija Tunevic).
• Debt Forgiveness Agreements on January 1, 2025, with William Hisey ($5,869.86), Kenneth L Waggoner ($161,739.13), Percy Kwong ($300,000), and Danny Rittman ($375,000).

Stakeholder Impact

• Shareholders face potential for significant dilution from future equity offerings, volatility in stock price (OTC QB), and limited marketability due to penny stock regulations. Existing shareholders bear the burden of increased accumulated deficit and working capital deficit. The strategic pivot to biotech could offer long-term growth potential but also introduces new risks.
• Employees and management experience high turnover in key positions, indicating instability. Compensation agreements often involve stock, tying their interests to share performance. Debt forgiveness agreements for former executives impact company liabilities.
• Creditors face higher risk due to increased total liabilities and a going concern warning, especially those with unsecured, non-interest bearing, or convertible notes.
• Customers of existing AI/IT consulting services might experience impacts on continuity or development due to the strategic shift and focus on new joint ventures. New biotech ventures aim to positively impact society (e.g., healthcare).

Next Steps

• Raise additional investment capital to fund operating expenses and implement the business plan.
• Pursue a revised equity financing structure with a higher minimum floor price of $2 per share.
• Continue development and commercialization efforts for AI technologies (Avant! AI, InstantFAME, Ainnova Tech).
• Formally establish and operate Klothonova Inc. and Insulinova, Inc. joint ventures with Austrianova, contributing capital and resources.
• Address the identified ineffectiveness of disclosure controls and procedures.
• Seek FINRA approval for the name change to Ava Bio, Inc. and a potential new trading symbol.

Key Dates

Recommendation

The company exhibits severe financial distress with no revenue, a substantial and growing accumulated deficit, and a significant working capital deficit. The explicit "going concern" warning from management and auditors highlights fundamental viability issues. While a strategic pivot to biotech and a reduced net loss are noted, these are overshadowed by the lack of a stable revenue stream, increasing liabilities, and ineffective internal controls. The high management turnover and reliance on dilutive financing further compound the risk. The termination of a previous financing agreement to seek a higher floor price, while potentially beneficial in theory, does not guarantee successful capital acquisition, which is critical for survival. Given these fundamental weaknesses and high operational risk, the stock is highly speculative and carries significant downside risk.

Keywords

AI technology, Biotechnology, Cell encapsulation, Joint venture, SEC filing, 10-Q, Financial results, Net loss, Going concern, Capital raise, Corporate governance, Management changes, OTC Markets, Ava Bio Inc, Avant Technologies Inc, Klothonova, Insulinova, Unsupervised learning, Diabetic Retinopathy detection